# Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

> **NCT02442466** · EARLY_PHASE1 · TERMINATED · sponsor: **MelCure SA** · enrollment: 5 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Endothelin Receptor B inhibitor BQ788
- **DRUG:** PBS

## Key facts

- **NCT ID:** NCT02442466
- **Lead sponsor:** MelCure SA
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-05
- **Final completion:** —
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Difficulties to recruit on time the required patient population.
- **Last updated:** 2015-05-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442466, "Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02442466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*